Posted on

Could a psychedelic vaccine prevent depression?

A New Vaccine Against Depression? | MYND Life Sciences

While many psychedelics companies are developing treatments for depression, MYND Life Sciences hopes to prevent depression from developing in the first place.

MYND recently signed a licensing agreement with Eyam, a private vaccine developer, to create a vaccine that would prevent neurological disorders including depression. The underlying theory is that depression is essentially neuro-inflammation, and psychedelics may have an anti-inflammatory effect that could prevent the neuro-inflammatory process.

PDF of article

Posted on

If you missed the cannaBUS, jump on the psilocybin train

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More

Now is the time to buy these 10 psychedelic stocks.

When the cannabis company GW Pharmaceuticals sold for billions earlier this year, those who didn’t invest were left with major regret. If you missed out on cannabis, now is your chance to be an early investor in the shroom boom as psychedelic companies begin to follow a similar pathway. These 10 companies are worth the buy according to Maxim Group’s latest analysis.

PDF of article

Posted on

Maxim Group says Mindset Pharma is a ‘Buy’

Maxim Group initiates coverage of Mindset Pharma with a ‘Buy’ rating and price target of US$1

If you want to triple your investment in a year, keep an eye on Mindset Pharma. Mindset currently trades at C$0.45 in Canada (MSET) and US$0.36 in the States (MSSTF), but Maxim Group predicts that the price could go reach US$1 in 12 months, giving the company a ‘buy’ rating. Maxim analysts note that Mindset’s psilocybin compound, MSP-1014, is cheaper to produce than psilocybin and has a relatively short path to market, while Mindset’s other “purpose-designed” compounds could potentially be “best-in-class in the longer term.”

PDF of article

Posted on

California gets one step closer to legalizing psychedelics

California Lawmakers Approve Bill To Legalize Psychedelics Possession In Committee

If you’ve been following along with the Daily Mushroom newsletter, you know that earlier this month, the California Senate approved a bill that would decriminalize possession of psychedelic drugs like magic mushrooms. Well, that bill (SB 5119) was just approved by The Assembly Public Safety Committee – one of three assembly committees needed to advance the legislation before reaching the governor’s desk.

Senator Scott Wiener, the bill’s sponsor, turned to Twitter to celebrate the win. “Another step toward ending the failed & racist War on Drugs & expanding access to mental health & addiction treatment.”

PDF of article

Posted on

Compass Pathways conducts world’s largest psilocybin therapy trial

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression

Move over Prozac, Compass Pathways (CMPS) just made major progress in psychedelic treatment for depression. The company is conducting the world’s largest psilocybin therapy trial for its proprietary psychedelic compound, COMP360, which targets treatment-resistant depression. So far, 216 patients have had psilocybin therapy sessions at Compass’s 22 trial sites across 10 countries, with 14 more patients completing sessions over the next two weeks. Researchers will follow-up with each patient 12 weeks after the sessions and will publish the findings by the end of this year. Other studies have found that psilocybin is 4 times more effective than typical antidepressants – let’s see what Compass’s new research reveals.

Posted on

Bob Marley’s family launches functional and psychedelic mushroom brand with Silo Wellness

Marley One Launches The First Global Functional And Psychedelic Mushroom Brand

Don’t worry about a thing – Bob Marley’s family is partnering with Silo Wellness (SILO) to launch the first global consumer brand of functional and psychedelic mushrooms, Marley One. The first round of products will be a line of functional mushroom tinctures for a variety of benefits such as immunity, sleep, cognitive function, and gut support. The psychedelic mushroom products will be introduced later this year, followed by functional mushroom gummies, capsules, and cosmetics. Cedella Marley hopes that “these products will empower people to experience oneness with nature and the universe at large – and ultimately, achieve greater self-actualization.”

PDF of article